Senseonics Eversense 365 glucose monitor cleared in the U.S.
by
Contributor since / Followers
Contributor since / Followers
3 months ago
Grandbrothers/iStock Editorial via Getty Images
- Senseonics (NYSE:SENS) and its partner Ascensia Diabetes Care announced Tuesday that the U.S. FDA cleared their next-generation continuous glucose monitoring (CGM) system, Eversense 365.
- Accordingly, the fully implantable CGM device will be available in the U.S. for people with Type 1 and Type 2 diabetes aged 18 years and older.
- Eversense 365 is the world’s first one-year CGM system, and it is highly differentiated from short-term CGMs, the duo said.
- Ascensia, owned by Japanese medical device maker PHC Holdings Corporation (OTCPK:PHCCF), plans to begin the product’s U.S. launch in Q4 2024.
- “Extending sensor longevity to a full year, coupled with seamless device connectivity and a high level of accuracy, provides both freedom and peace of mind to patients living with diabetes,” said Senseonics (SENS) CEO Tim Goodnow.
- Senseonics (SENS) operates in the CGM market dominated by Medtronic (MDT), Abbott Laboratories (ABT), and Dexcom (DXCM).